Calixar aims to become a leader in early drug discovery segment through unique technology and pipeline of novel and high-quality therapeutic targets Funds will enable company to isolate around 100 priority targets for the pharmaceutical industry.
Starting from native material or recombinant systems, we succeed with all types of proteins: Kinases, Phosphatases, Ubiquitins, Epigenetic Proteins, GPCRs, Ion Channels, Transporters, Receptors and Viral Proteins.
Eurofins CALIXAR’s approach allows to preserve the original structure and function of recombinant proteins (Kinases, Phosphatases, Ubiquitin, Epigenetic Proteins, GPCRs, Ion Channels, Transporters, Receptors, Anchors and Viral Proteins) providing solutions for pharmaceutical industries, biotechnology companies and academic teams to develop conformational antibodies, formulate new vaccines, carry out Structure Based Drug Discovery and/or HTS assays.
